Q2 2018 13F Holders as of 30 Jun 2018
-
Type / Class
-
Equity / Common Stock, par value $0.00001
-
Shares outstanding
-
62,162,717
-
Total 13F shares
-
13,927,964
-
Share change
-
+1,993,826
-
Total reported value
-
$93,611,738
-
Price per share
-
$6.72
-
Number of holders
-
68
-
Value change
-
+$10,872,610
-
Number of buys
-
41
-
Number of sells
-
37
Institutional Holders of Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) as of Q2 2018
As of 30 Jun 2018,
Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) was held by
68 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
13,927,964 shares.
The largest 10 holders included
FMR LLC, GREAT POINT PARTNERS LLC, BVF INC/IL, FARALLON CAPITAL MANAGEMENT LLC, Pharmstandard International S.A., VANGUARD GROUP INC, ADAGE CAPITAL PARTNERS GP, L.L.C., RENAISSANCE TECHNOLOGIES LLC, Cormorant Asset Management, LP, and DEUTSCHE BANK AG\.
This page lists
68
institutional shareholders reporting positions in this security
for the Q2 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.